Quest Diagnostics beat first-quarter 2025 earnings estimates and raised its full-year profit and revenue forecasts for both 2025 and 2026, Reuters reported. The company attributed the raised outlook to strong and continued demand for diagnostic testing. The 2026 profit and revenue forecasts exceeded analyst consensus estimates, according to Reuters.
The decision to raise guidance across two fiscal years suggests Quest sees durable demand tailwinds in the commercial laboratory market. The move contrasts with trends at adjacent diagnostics and sequencing firms: Illumina cut its full-year revenue guidance and announced a $100 million cost reduction program, citing a China sales ban and biotech funding weakness, while GRAIL faces reimbursement uncertainty as health-economic models project cost-effectiveness figures between $50,000 and $100,000 per quality-adjusted life year.
The results carry implications for Labcorp, Quest's closest peer, which recently announced a co-commercialization deal with Illumina for oncology IVD tests. If Quest's volume trends reflect broader market strength rather than share gains alone, they would signal positive conditions across the independent lab sector.
The dossier does not include specific dollar figures for Quest's updated guidance ranges, making it difficult to assess how much of the raise reflects organic volume growth versus pricing, acquisitions, or test mix shift toward higher-reimbursement assays. Quest has historically supplemented organic growth through tuck-in acquisitions.
The next markers to watch are Quest's full Q1 earnings release details and Labcorp's upcoming quarterly report, which will offer a cross-check on whether industry-wide lab demand is as strong as Quest's guidance revision implies.